Immunological Rare Disease Market: By Drug Class, Fusion Proteins, Immunosuppressants, and Others), By Disease Indication, By Distribution Channel, and Geography

Immunological Rare Disease Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Monoclonal Antibody (mAb), Fusion Proteins, Immunosuppressants, and Others), By Disease Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region

Immunological Rare Disease Market size was valued at US$ X million in 2023 and is poised to grow at a significant CAGR of 12.2% from 2024-2030 The immune system is delegated to defend the body from attacks from outside or inside. Many diseases can affect the immune system reducing its ability to defend itself or inducing an abnormal response against external or internal antigens. Immunological Rare diseases, often known as orphan diseases, afflict a small percentage of the population at any given time. Orphan medications are those that are suggested for the treatment of rare disorders. An orphan immunological disease affects less than 200,000 persons in the United States, according to the Food and Drug Administration (FDA).

Furthermore, Several diseases can affect the immune system. Disorders associated with a reduced response against no self-antigens are called immunodeficiencies. On the other hand, primary immunodeficiencies (PIDs) are in most cases rare diseases associated with specific, genetic mutations. Immunology medications or substances modify immune responses by enhancing or inhibiting the immune system. They are used to fight infections as well as to prevent or cure autoimmune or immunological illnesses such as rheumatoid arthritis, psoriatic arthritis, type 1 diabetes, and others.    Rising awareness about rare immunological diseases such as Hypoalbuminemia and Hypovolemia, and Severe Congenital Protein C Deficiency in both developing and developed nations and the rising occurrence of immunological disorders due to environmental factors are critical reasons for increasing the demand for rear immunological drugs in the market. 

Immunological Rare Disease Market Key Developments

  • In May 2022, Pfizer Inc. strengthened its product portfolio by acquiring Arena Pharmaceuticals, a business that discovers revolutionary potential treatments for the treatment of many immuno-inflammatory diseases.

Immunological Rare Disease Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

12.2%

Largest Market

North America

Fastest Growing Market

Asia Pacific

Immunological Rare Disease Market Dynamics

A variety of variables, including hazardous chemical exposure, stress, dietary components, gut dysbiosis, and infections, all contribute to an increase in the number of persons suffering from rear immunological disorders. Immunological rare disease problems are now the most common cause of chronic illness in the United States, with a considerable number of individuals suffering from at least one form of rear immunological disease.

For instance, according to a study published by the National Stem Cell Foundation, roughly 4% of the world's population is afflicted with at least one of 80 or more with Immunological rear diseases. The rising demand for these treatments among the patient population is pushing industry participants' aggressive attempts to develop and introduce new pharmaceuticals into the market. As a result, the pipeline portfolio of leading immunology companies is expanding dramatically. For instance, there are around 30 pipeline projects of Sanofi in the immunology segment and around 20 pipeline candidates of Johnson & Johnson Services.

Immunological Rare Disease Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market CAGR

12.2%

By Drug Class

  • Monoclonal Antibody
  • Immunosuppressants
  • Fusion Proteins
  • Others

By Disease Indication

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Plaque Psoriasis
  • Ankylosing Spondylitis
  • Inflammatory Bowel Disease
  • Prophylaxis of Organ Rejection
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA

Key Features of the Report

  • The immunological rare disease market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Download Free Sample Report

LOCATION

Geography

geography

Frequently Asked Questions

The immunological rare disease market market size was valued at US$ x million in 2023 and is projected to grow at a CAGR of 12.2% from 2024 to 2030.

The market key players are: AbbVie, Inc. (U.S.) Janssen Global Services, LLC (U.S.) Eli Lilly and Company (U.S.) Novartis AG (Switzerland) Pfizer Inc. (U.S.) Bristol-Myers Squibb Company (U.S.) Merck Sharp & Dohme Corp. (U.S.) F. Hoffmann-La Roche Ltd. (Switzerland) Amgen Inc. (U.S.) Astellas Pharma Inc. (Japan) UCB SA (Belgium)

The market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary
2. Global Immunological Rare Disease Market Introduction 
2.1.Global Immunological Rare Disease Market  - Taxonomy
2.2.Global Immunological Rare Disease Market  - Definitions
2.2.1.Drug Class
2.2.2.Disease Indication
2.2.3.Distribution Channel
2.2.4.Geography
2.2.5.Region
3. Global Immunological Rare Disease Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Immunological Rare Disease Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Immunological Rare Disease Market  By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Monoclonal Antibody
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Immunosuppressants
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Fusion Proteins
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Others
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6. Global Immunological Rare Disease Market  By Disease Indication, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Rheumatoid Arthritis
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Psoriatic Arthritis
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Plaque Psoriasis
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Ankylosing Spondylitis
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Inflammatory Bowel Disease
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
6.6. Prophylaxis of Organ Rejection
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.6.3. Market Opportunity Analysis 
6.7. Others
6.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.7.3. Market Opportunity Analysis 
7. Global Immunological Rare Disease Market  By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Online Pharmacies
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8. Global Immunological Rare Disease Market  By Geography, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. The Asia Pacific
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Latin America
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. MEA
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9. Global Immunological Rare Disease Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10. North America Immunological Rare Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Monoclonal Antibody
10.1.2.Immunosuppressants
10.1.3.Fusion Proteins
10.1.4.Others
10.2.  Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Rheumatoid Arthritis
10.2.2.Psoriatic Arthritis
10.2.3.Plaque Psoriasis
10.2.4.Ankylosing Spondylitis
10.2.5.Inflammatory Bowel Disease
10.2.6.Prophylaxis of Organ Rejection
10.2.7.Others
10.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Online Pharmacies
10.4.  Geography Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.North America
10.4.2.Europe
10.4.3.The Asia Pacific
10.4.4.Latin America
10.4.5.MEA
10.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11. Europe Immunological Rare Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Monoclonal Antibody
11.1.2.Immunosuppressants
11.1.3.Fusion Proteins
11.1.4.Others
11.2.  Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Rheumatoid Arthritis
11.2.2.Psoriatic Arthritis
11.2.3.Plaque Psoriasis
11.2.4.Ankylosing Spondylitis
11.2.5.Inflammatory Bowel Disease
11.2.6.Prophylaxis of Organ Rejection
11.2.7.Others
11.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Online Pharmacies
11.4.  Geography Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.North America
11.4.2.Europe
11.4.3.The Asia Pacific
11.4.4.Latin America
11.4.5.MEA
11.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
11.5.6.Rest of EU
12. Asia Pacific (APAC) Immunological Rare Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Monoclonal Antibody
12.1.2.Immunosuppressants
12.1.3.Fusion Proteins
12.1.4.Others
12.2.  Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Rheumatoid Arthritis
12.2.2.Psoriatic Arthritis
12.2.3.Plaque Psoriasis
12.2.4.Ankylosing Spondylitis
12.2.5.Inflammatory Bowel Disease
12.2.6.Prophylaxis of Organ Rejection
12.2.7.Others
12.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Online Pharmacies
12.4.  Geography Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.North America
12.4.2.Europe
12.4.3.The Asia Pacific
12.4.4.Latin America
12.4.5.MEA
12.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13. Middle East and Africa (MEA) Immunological Rare Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Monoclonal Antibody
13.1.2.Immunosuppressants
13.1.3.Fusion Proteins
13.1.4.Others
13.2.  Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Rheumatoid Arthritis
13.2.2.Psoriatic Arthritis
13.2.3.Plaque Psoriasis
13.2.4.Ankylosing Spondylitis
13.2.5.Inflammatory Bowel Disease
13.2.6.Prophylaxis of Organ Rejection
13.2.7.Others
13.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Online Pharmacies
13.4.  Geography Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.North America
13.4.2.Europe
13.4.3.The Asia Pacific
13.4.4.Latin America
13.4.5.MEA
13.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14. Latin America Immunological Rare Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
14.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Monoclonal Antibody
14.1.2.Immunosuppressants
14.1.3.Fusion Proteins
14.1.4.Others
14.2.  Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Rheumatoid Arthritis
14.2.2.Psoriatic Arthritis
14.2.3.Plaque Psoriasis
14.2.4.Ankylosing Spondylitis
14.2.5.Inflammatory Bowel Disease
14.2.6.Prophylaxis of Organ Rejection
14.2.7.Others
14.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Hospital Pharmacies
14.3.2.Retail Pharmacies
14.3.3.Online Pharmacies
14.4.  Geography Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.North America
14.4.2.Europe
14.4.3.The Asia Pacific
14.4.4.Latin America
14.4.5.MEA
14.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.AbbVie, Inc. (U.S.)
15.2.2.Janssen Global Services, LLC (U.S.)
15.2.3. Eli Lilly and Company (U.S.)
15.2.4.Novartis AG (Switzerland)
15.2.5.Pfizer Inc. (U.S.)
15.2.6.Bristol-Myers Squibb Company (U.S.)
15.2.7.Merck Sharp & Dohme Corp. (U.S.)
15.2.8.F. Hoffmann-La Roche Ltd. (Switzerland)
15.2.9.Amgen Inc. (U.S.)
15.2.10.Astellas Pharma Inc. (Japan)
15.2.11.UCB SA (Belgium)
16. Research Methodology 
17. Appendix and Abbreviations 

Key Market Players

  • AbbVie, Inc. (U.S.)
  • Janssen Global Services, LLC (U.S.)
  • Eli Lilly and Company (U.S.)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • Merck Sharp & Dohme Corp. (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Amgen Inc. (U.S.)
  • Astellas Pharma Inc. (Japan)
  • UCB SA (Belgium)

Related Industry Reports